Press Releases InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing September 22, 2020 Read More » InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update September 8, 2020 Read More » InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020 September 2, 2020 Read More » InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755 July 7, 2020 Read More » InMed Announces Completion of Share Consolidation June 30, 2020 Read More » InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System June 24, 2020 Read More » InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation June 19, 2020 Read More » InMed Releases CBN Preclinical Results in Glaucoma May 27, 2020 Read More » InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family May 19, 2020 Read More » InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update May 14, 2020 Read More » InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update May 14, 2020 Read More » InMed Files PCT Patent Application for Neuroprotection in Glaucoma May 12, 2020 Read More » Notice of Telephone Scam Impersonating InMed May 8, 2020 Read More » InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020 May 8, 2020 Read More » InMed to Present at Canaccord Genuity’s 4th Annual Cannabis Conference May 7, 2020 Read More » InMed and Almac Group Developing Improved Cannabinoid Production Methods May 5, 2020 Read More » InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755 April 30, 2020 Read More » InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects April 1, 2020 Read More » InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial March 24, 2020 Read More » InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak March 20, 2020 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Next » Management Learn More Board of Directors Learn More Scientific Advisory Board Learn More Investor Alerts Sign up to receive news releases from InMed Pharmaceuticals. SIGN UP
InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update September 8, 2020 Read More »
InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020 September 2, 2020 Read More »
InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System June 24, 2020 Read More »
InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation June 19, 2020 Read More »
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update May 14, 2020 Read More »
InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update May 14, 2020 Read More »
InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020 May 8, 2020 Read More »
InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755 April 30, 2020 Read More »
InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects April 1, 2020 Read More »
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial March 24, 2020 Read More »
InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak March 20, 2020 Read More »